Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient.
We describe the case of an acromegalic subject, who was the first patient ever treated with the GH receptor antagonist pegvisomant. Furthermore, in this particular patient, progression in tumor size was encountered during treatment with pegvisomant. The patient described did benefit from cotreatment with pegvisomant and octreotide, including decreased GH levels, normalization of serum insulin-like growth factor I concentrations, and improvement of visual field defects.
van der Lely
A J
AJ
Department of Internal Medicine, Erasmus University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands. vanderlely@inw3.azr.nl
Muller
A
A
Janssen
J A
JA
Davis
R J
RJ
Zib
K A
KA
Scarlett
J A
JA
Lamberts
S W
SW
D000172:Acromegaly / Q000188:drug therapy / Q000209:etiology*; D000236:Adenoma / Q000150:complications / Q000188:drug therapy* / Q000601:surgery; D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D019382:Human Growth Hormone / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D015282:Octreotide / Q000627:therapeutic use*; D010911:Pituitary Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000601:surgery; D011986:Receptors, Somatotropin / Q000037:antagonists & inhibitors
D018931:Antineoplastic Agents, Hormonal; D011986:Receptors, Somatotropin; D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I; C406545:pegvisomant; D015282:Octreotide